Brief: Almirall Enters Collaboration With Huaota For Development Of Monoclonal Antibody In Medical Dermatology
27/03/2026 10:42
March 27 (Reuters) - Almirall SA ALM.MC: ENTERS COLLABORATION WITH HUAOTA FOR DEVELOPMENT OF A NOVEL MONOCLONAL ANTIBODY IN MEDICAL DERMATOLOGY HUAOTA WILL CONDUCT EARLY RESEARCH AND INITIAL CLINICAL DEVELOPMENT , WHILE ALMIRALL HOLDS GLOBAL RIGHTS OUTSIDE CHINA CUMULATIVE PAYMENTS BY ALMIRALL TO HUAOTA COULD SUM UP TO USD $340 MILLION HUAOTA WILL PAY TIERED ROYALTIES TO ALMIRALL BASED ON POTENTIAL FUTURE SALES OF THE PRODUCT IN CHINA Source text Further company coverage: ALM.MC (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Almirall
See all newsBrief: Almirall Says Phase 3B Adlong Clinical Study Show Treatment Outcomes With Up To Five Years Of Lebrikizumab
Brief: Almirall And CrystalO To Discover, Develop Novel Small Molecules In Medical Dermatology
Almirall shares rise as lower costs beat EBITDA estimates
Brief: Almirall, Certest Biotec Sign Deal to Develop Rare Dermatology Treatments
Spanish stocks - Factors to watch on July 24